Pediatric trials aim to expand GLP-1 weight loss drugs to younger children

A recent report from The Washington Times explores emerging clinical trials studying GLP-1 medications for treating obesity in children younger than 12. Originally developed to manage diabetes, drugs such as Ozempic, Wegovy, and Mounjaro are now being evaluated for their potential role in pediatric obesity care as childhood obesity rates continue to climb.

The article highlights insights from Dr. Evan Nadler, former head of the Childhood Obesity Program at Children’s National Hospital, who emphasizes that severe obesity can require medical intervention even at very young ages. Drawing on his extensive clinical experience, Dr. Nadler notes that treatments like GLP-1 medications may become an important option within a broader, multidisciplinary care approach that includes nutrition, psychological support, and lifestyle guidance.

As researchers continue studying safety and long-term outcomes, the piece underscores the growing conversation among physicians about how best to address childhood obesity as a serious medical condition rather than a cosmetic concern.

Read the full article here.